文献速递心力衰竭与心肌病

急性心衰患者袢利尿剂治疗时间与院内死亡率的关系

Time-to-Furosemide Treatment and Mortality in Patients Hospitalized With Acute Heart Failure.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

REALITY-AHF 为前瞻性多中心观察性队列研究,纳入 1,291 例经急诊入院并在 24 小时内接受静脉呋塞米的急性心衰患者,评估从到达急诊至首次静脉呋塞米注射的时间(D2F)与全因院内死亡率的关系。D2F 中位数为 90 分钟,早期治疗组(D2F<60 分钟)院内死亡率显著低于非早期组,多因素分析显示更早治疗仍与更低院内死亡率独立相关。

要点

  • D2F 中位数 90 分钟,仅 37.3% 患者于 60 分钟内接受静脉呋塞米。
  • 早期治疗组院内死亡率 2.3%,非早期组 6.0%(p=0.002)。
  • 多因素分析 OR 0.39(95%CI 0.20–0.76,p=0.006),支持尽早给药。

核心结论

  • 在经急诊入院的急性心衰患者中,更早接受静脉袢利尿剂治疗与更低的院内全因死亡率相关。

研究设计与样本

  • REALITY-AHF 为前瞻性、多中心、观察性队列研究,主要评估急诊急性心衰患者至袢利尿剂治疗时间与临床结局的关联。
  • 共纳入 1,291 例经急诊入院并在到达后 24 小时内接受静脉呋塞米的急性心衰患者。
  • D2F 时间定义为患者到达急诊至首次静脉呋塞米注射的时间,D2F<60 分钟预先定义为早期治疗组。

主要发现

  • D2F 中位时间为 90 分钟(IQR 36–186 分钟),481 例(37.3%)归入早期治疗组。
  • 早期治疗组患者更常经救护车到达且充血体征更多。
  • 院内死亡率早期治疗组为 2.3%,非早期治疗组为 6.0%(p=0.002)。
  • 多因素分析显示更早治疗仍与更低院内死亡率显著相关(OR 0.39;95%CI 0.20–0.76;p=0.006)。

临床怎么用

  • 对经急诊就诊的急性心衰患者,应尽早启动静脉袢利尿剂治疗以降低院内死亡风险。

局限性

  • 为观察性队列研究,早期治疗与较低死亡率之间为关联而非因果结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute heart failure (AHF) is a life-threatening disease requiring urgent treatment, including a recommendation for immediate initiation of loop diuretics. OBJECTIVES: The authors prospectively evaluated the association between time-to-diuretic treatment and clinical outcome. METHODS: REALITY-AHF (Registry Focused on Very Early Presentation and Treatment in Emergency Department of Acute Heart Failure) was a prospective, multicenter, observational cohort study that primarily aimed to assess the association between time to loop diuretic treatment and clinical outcome in patients with AHF admitted through the emergency department (ED). Door-to-furosemide (D2F) time was defined as the time from patient arrival at the ED to the first intravenous furosemide injection. Patients with a D2F time <60 min were pre-defined as the early treatment group. Primary outcome was all-cause in-hospital mortality. RESULTS: Among 1,291 AHF patients treated with intravenous furosemide within 24 h of ED arrival, the median D2F time was 90 min (IQR: 36 to 186 min), and 481 patients (37.3%) were categorized as the early treatment group. These patients were more likely to arrive by ambulance and had more signs of congestion compared with the nonearly treatment group. In-hospital mortality was significantly lower in the early treatment group (2.3% vs. 6.0% in the nonearly treatment group; p = 0.002). In multivariate analysis, earlier treatment remained significantly associated with lower in-hospital mortality (odds ratio: 0.39; 95% confidence interval: 0.20 to 0.76; p = 0.006). CONCLUSIONS: In this prospective multicenter, observational cohort study of patients presenting at the ED for AHF, early treatment with intravenous loop diuretics was associated with lower in-hospital mortality. (Registry focused on very early presentation and treatment in emergency department of acute heart failure syndrome; UMIN000014105).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Matsue Y, Damman K, Voors AA, et al. Time-to-Furosemide Treatment and Mortality in Patients Hospitalized With Acute Heart Failure. J Am Coll Cardiol. 2017. PMID: 28641794. doi:10.1016/j.jacc.2017.04.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。